ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Celltrion, Inc.

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

 

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

 

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

 

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2019 KRWUSD
Revenue1,128.45B967.65M
Gross Profit623,222.91M534.41M
Operating income378,062.36M324.18M
Income before tax374,013.70M320.71M
Net income297,556.85M255.15M
EBITDA537,282.22M460.71M
Diluted EPS2,218.681.90
Dividends Per Share00
Total Assets3,893.69B3,366.93M
Total liabilities986,733.41M853.24M
Total equity2,794.15B2,416.14M
Operating cash flow468,031.66M401.33M
Currency in KRWCurrency in USD

Historical Data

 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 603,412.76M 670,580.96M 949,079.96M 982,074.95M 1,128.45B
Gross Profit 361,042.87M 388,407.95M 685,318.99M 541,284.44M 623,222.91M
Operating income 258,922.92M 249,614.31M 507,771.41M 338,291.33M 378,062.36M
Income before tax 162,901.39M 228,752.75M 491,503.19M 317,725.82M 374,013.70M
Net income 154,089.61M 177,994.50M 382,467.03M 261,841.76M 297,556.85M
EBITDA 341,097.00M 338,289.64M 605,721.68M 465,057.52M 537,282.22M
Diluted EPS 1,187.40 1,330.99 2,794.58 1,943.56 2,218.68
Dividends Per Share 0 0 0 0 0
Total Assets 2,825.98B 3,117.56B 3,410.79B 3,628.33B 3,893.69B
Total liabilities 1,015.16B 914,607.61M 975,863.55M 992,561.59M 986,733.41M
Total equity 1,694.23B 2,053.63B 2,308.89B 2,524.02B 2,794.15B
Operating cash flow 45,199.75M 230,062.47M 482,870.20M 372,074.18M 468,031.66M
 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 533.14M 577.99M 839.51M 892.37M 967.65M
Gross Profit 318.99M 334.77M 606.20M 491.84M 534.41M
Operating income 228.77M 215.14M 449.15M 307.39M 324.18M
Income before tax 143.93M 197.16M 434.76M 288.70M 320.71M
Net income 136.14M 153.41M 338.31M 237.92M 255.15M
EBITDA 301.37M 291.58M 535.79M 422.58M 460.71M
Diluted EPS 1.04 1.14 2.47 1.76 1.90
Dividends Per Share 0 0 0 0 0
Total Assets 2,410.12M 2,581.19M 3,186.01M 3,251.78M 3,366.93M
Total liabilities 865.77M 757.25M 911.55M 889.55M 853.24M
Total equity 1,444.91M 1,700.31M 2,156.73M 2,262.07M 2,416.14M
Operating cash flow 39.93M 198.29M 427.12M 338.09M 401.33M

Valuation Measures

Dec 2019
PER81.17
ROA7.91%
ROE11.19%
Operating margin33.50%
Profit margin26.36%

Key executives

  • Chief Executive Officer & Director: Wu-Sung Ki
  • Finance Director: Ho-Seop Lee
  • Head-Legal & Compliance Support: Sung-Han Lee
  • Vice President: Sang-Joon Lee
  • Vice President: Jung-Won Yoon

Shareholders

  • SEO JUNG-JIN (22.1%)
  • National Pension Service of Korea (9.1%)
  • Temasek Holdings Pte Ltd. (Investment Management) (7.4%)
  • The Vanguard Group, Inc. (2.1%)
  • BlackRock Fund Advisors (1.5%)
  • Celltrion, Inc. (0.8%)
  • Norges Bank Investment Management (0.8%)
  • Samsung Asset Management Co., Ltd. (0.7%)
  • Mirae Asset Global Investments Co., Ltd. (0.7%)
  • Celltrion Inc. Employee Stock Ownership ASSN. (0.5%)

Contact Details

Related Companies

  • Celltrion Inc. Employee Stock Ownership ASSN.
  • Celltrion Pharm Inc.

Competitors

  • Novartis AG
  • Pfizer Inc.
  • Mylan N.V.
  • AbbVie, Inc.
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Biocon Limited
  • Merck KGaA
  • SAMSUNG BIOLOGICS Co., Ltd.
  • EPIRUS Biopharmaceuticals, Inc.
  • Reyon Pharmaceutical Co., Ltd.
  • Wooridul Pharmaceutical Ltd.
  • Sinocelltech Group Limited Class A
  • Mabion SA
  • ALTEOGEN Inc.
  • PharmAbcine Inc.
  • Dexter Studios Co., Ltd.
Last Updated on 12 Aug, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media